{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:33:24Z","timestamp":1793662404201,"version":"4.5.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s00198-026-07968-w","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T13:22:10Z","timestamp":1775827330000},"page":"1811-1820","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Romosozumab versus teriparatide and risk of all-cause mortality in patients with osteoporosis: a real-world propensity score-matched cohort study"],"prefix":"10.1007","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6993-5416","authenticated-orcid":false,"given":"Sung Huang Laurent","family":"Tsai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Hsuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ya","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Yu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Hsien","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Jen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng-Huang","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hung-En","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei Cheng Chung","family":"James","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,10]]},"reference":[{"issue":"Suppl 1","key":"7968_CR1","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.jfma.2023.01.007","volume":"122","author":"T-W Tai","year":"2023","unstructured":"Tai T-W, Huang C-F, Huang H-K et al (2023) Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: 2022 update. J Formos Med Assoc 122(Suppl 1):S4\u2013S13","journal-title":"J Formos Med Assoc"},{"key":"7968_CR2","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","volume":"399","author":"IR Reid","year":"2022","unstructured":"Reid IR, Billington EO (2022) Drug therapy for osteoporosis in older adults. Lancet 399:1080\u20131092","journal-title":"Lancet"},{"key":"7968_CR3","doi-asserted-by":"publisher","first-page":"S4","DOI":"10.1016\/j.bone.2005.11.024","volume":"38","author":"J-Y Reginster","year":"2006","unstructured":"Reginster J-Y, Burlet N (2006) Osteoporosis: a still increasing prevalence. Bone 38:S4-9","journal-title":"Bone"},{"key":"7968_CR4","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/S2213-8587(24)00092-5","volume":"12","author":"DM Black","year":"2024","unstructured":"Black DM, Thompson AR, Eastell R, Bouxsein ML (2024) Bone mineral density as a surrogate endpoint for fracture risk reduction in clinical trials of osteoporosis therapies: an update on SABRE. Lancet Diabetes Endocrinol 12:371\u2013373","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7968_CR5","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/S2666-7568(22)00293-8","volume":"4","author":"CL Gregson","year":"2023","unstructured":"Gregson CL (2023) CFracture, an alternative to QFracture that accounts for mortality to better predict fragility fracture risk. Lancet Healthy Longev 4:e6\u2013e7","journal-title":"Lancet Healthy Longev"},{"key":"7968_CR6","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1097\/GRF.0000000000000572","volume":"63","author":"M Mu\u00f1oz","year":"2020","unstructured":"Mu\u00f1oz M, Robinson K, Shibli-Rahhal A (2020) Bone health and osteoporosis prevention and treatment. Clin Obstet Gynecol 63:770\u2013787","journal-title":"Clin Obstet Gynecol"},{"key":"7968_CR7","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1038\/s41584-024-01120-w","volume":"20","author":"F Buttgereit","year":"2024","unstructured":"Buttgereit F, Palmowski A, Bond M et al (2024) Osteoporosis and fracture risk are multifactorial in patients with inflammatory rheumatic diseases. Nat Rev Rheumatol 20:417\u2013431","journal-title":"Nat Rev Rheumatol"},{"key":"7968_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1016\/j.mcna.2020.06.004","volume":"104","author":"CB Johnston","year":"2020","unstructured":"Johnston CB, Dagar M (2020) Osteoporosis in older adults. Med Clin North Am 104:873\u2013884","journal-title":"Med Clin North Am"},{"key":"7968_CR9","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S2213-8587(24)00073-1","volume":"12","author":"KA Ward","year":"2024","unstructured":"Ward KA, Madanhire T, Marenah K et al (2024) Disparities in fragility fracture and osteoporosis care in Africa. Lancet Diabetes Endocrinol 12:294\u2013296","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7968_CR10","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, Libanati C, Crittenden DB et al (2017) Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet 390:1585\u20131594","journal-title":"Lancet"},{"key":"7968_CR11","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41574-023-00866-9","volume":"19","author":"I Foessl","year":"2023","unstructured":"Foessl I, Dimai HP, Obermayer-Pietsch B (2023) Long-term and sequential treatment for osteoporosis. Nat Rev Endocrinol 19:520\u2013533","journal-title":"Nat Rev Endocrinol"},{"key":"7968_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s00198-021-06095-y","volume":"33","author":"S Singh","year":"2022","unstructured":"Singh S, Dutta S, Khasbage S et al (2022) A systematic review and meta-analysis of efficacy and safety of romosozumab in postmenopausal osteoporosis. Osteoporos Int 33:1\u201312","journal-title":"Osteoporos Int"},{"key":"7968_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijsu.2019.03.004","volume":"66","author":"F Yuan","year":"2019","unstructured":"Yuan F, Peng W, Yang C, Zheng J (2019) Teriparatide versus bisphosphonates for treatment of postmenopausal osteoporosis: a meta-analysis. Int J Surg 66:1\u201311","journal-title":"Int J Surg"},{"key":"7968_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(22)00188-6","volume":"4","author":"J Thorley","year":"2022","unstructured":"Thorley J (2022) NICE approves romosozumab for postmenopausal osteoporosis. Lancet Rheumatol 4:e532","journal-title":"Lancet Rheumatol"},{"key":"7968_CR15","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.jcot.2021.01.019","volume":"17","author":"A Sain","year":"2021","unstructured":"Sain A, Bansal H, Pattabiraman K, Sharma V (2021) Present and future scope of recombinant parathyroid hormone therapy in orthopaedics. J Clin Orthop Trauma 17:54\u201358","journal-title":"J Clin Orthop Trauma"},{"key":"7968_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1302\/2046-3758.61.BJR-2016-0085.R1","volume":"6","author":"L Osagie-Clouard","year":"2017","unstructured":"Osagie-Clouard L, Sanghani A, Coathup M et al (2017) Parathyroid hormone 1-34 and skeletal anabolic action. Bone Joint Res 6:14\u201321","journal-title":"Bone Joint Res"},{"key":"7968_CR17","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1016\/S2213-8587(19)30255-4","volume":"7","author":"JN Tsai","year":"2019","unstructured":"Tsai JN, Lee H, David NL et al (2019) Combination denosumab and high dose teriparatide for postmenopausal osteoporosis (DATA-HD): a randomised, controlled phase 4 trial. Lancet Diabetes Endocrinol 7:767\u2013775","journal-title":"Lancet Diabetes Endocrinol"},{"key":"7968_CR18","doi-asserted-by":"publisher","first-page":"e861","DOI":"10.1210\/clinem\/dgae173","volume":"110","author":"J Stokar","year":"2025","unstructured":"Stokar J, Szalat A (2025) Cardiovascular safety of romosozumab vs PTH analogues for osteoporosis treatment: a propensity-score-matched cohort study. J Clin Endocrinol Metab 110:e861\u2013e867","journal-title":"J Clin Endocrinol Metab"},{"key":"7968_CR19","first-page":"1968","volume":"318","author":"A Slomski","year":"2017","unstructured":"Slomski A (2017) Romosozumab prevents fractures in women with osteoporosis. JAMA 318:1968","journal-title":"JAMA"},{"key":"7968_CR20","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1002\/jbmr.3176","volume":"32","author":"TM Keaveny","year":"2017","unstructured":"Keaveny TM, Crittenden DB, Bolognese MA et al (2017) Greater gains in spine and hip strength for romosozumab compared with teriparatide in postmenopausal women with low bone mass. J Bone Miner Res 32:1956\u20131962","journal-title":"J Bone Miner Res"},{"key":"7968_CR21","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1111\/os.13136","volume":"13","author":"A Tian","year":"2021","unstructured":"Tian A, Jia H, Zhu S et al (2021) Romosozumab versus teriparatide for the treatment of postmenopausal osteoporosis: a systematic review and meta-analysis through a grade analysis of evidence. Orthop Surg 13:1941\u20131950","journal-title":"Orthop Surg"},{"key":"7968_CR22","doi-asserted-by":"publisher","unstructured":"Yoshiyama T, Fukasawa T, Masuda S, Matsuda S, Kawakami K (2025) Persistence of romosozumab vs. teriparatide inJapanese older adults aged \u2265 75 years with osteoporosis: A population-based cohort study. Arch Osteoporos 21(1):14. https:\/\/doi.org\/10.1007\/s11657-025-01646-w","DOI":"10.1007\/s11657-025-01646-w"},{"key":"7968_CR23","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, Petersen J, Brandi ML et al (2017) Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med 377:1417\u20131427","journal-title":"N Engl J Med"},{"key":"7968_CR24","doi-asserted-by":"publisher","unstructured":"Lewiecki EM, Blicharski T, Goemaere S, Lippuner K, Meisner PD, Miller PD, Miyauchi A, Maddox J, Chen L, Horlait S (2018) A Phase III randomized placebo-controlled trial to evaluate efficacy and safety of romosozumab in men with osteoporosis. J Clin Endocrinol Metab 103(9):3183\u20133193.\u00a0https:\/\/doi.org\/10.1210\/jc.2017-02163","DOI":"10.1210\/jc.2017-02163"},{"key":"7968_CR25","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s40264-024-01475-9","volume":"48","author":"S-H Cheng","year":"2025","unstructured":"Cheng S-H, Chu W, Chou W-H et al (2025) Cardiovascular safety of romosozumab compared to commonly used anti-osteoporosis medications in postmenopausal osteoporosis: a systematic review and network meta-analysis of randomized controlled trials. Drug Saf 48:7\u201323","journal-title":"Drug Saf"},{"key":"7968_CR26","first-page":"107","volume":"48","author":"RMY Wong","year":"2024","unstructured":"Wong RMY, Wong PY, Liu C et al (2024) Treatment effects, adverse outcomes and cardiovascular safety of romosozumab - existing worldwide data: a systematic review and meta-analysis. J Orthop Transl 48:107\u2013122","journal-title":"J Orthop Transl"},{"key":"7968_CR27","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1007\/s00774-024-01531-5","volume":"42","author":"T Kobayashi","year":"2024","unstructured":"Kobayashi T, Hara M, Shimanoe C et al (2024) Efficacy and safety of romosozumab: a meta-analysis of placebo-controlled trials. J Bone Miner Metab 42:492\u2013502","journal-title":"J Bone Miner Metab"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07968-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07968-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-026-07968-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T21:02:16Z","timestamp":1792270936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-026-07968-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["7968"],"URL":"https:\/\/doi.org\/10.1007\/s00198-026-07968-w","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"None.","order":1,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}